Tuesday, April 14, 2026

by Adam Irvine, Staff Writer, Physicians Office Resource

Screening for iron deficiency, anemia, and lead exposure remains a foundational component of preventive care in primary care practice, particularly across pediatrics, women’s health, and vulnerable populations. However, recent evidence has begun to reshape how clinicians approach screening—shifting away from a model focused primarily on detecting overt disease toward one that emphasizes earlier identification, improved biomarkers, and more nuanced risk-based strategies.

Historically, screening efforts have centered on identifying anemia through hemoglobin testing and detecting lead exposure at higher thresholds. While these approaches remain important, they are increasingly recognized as insufficient for capturing early or subclinical disease. Iron deficiency without anemia, for example, can still significantly impact patient well-being, while even low levels of lead exposure have been shown to cause measurable neurodevelopmental harm. As a result, primary care physicians are being asked to rethink traditional screening paradigms and adopt a more proactive and comprehensive approach.

Iron Deficiency: A Shift Toward Earlier Recognition

Iron deficiency is among the most prevalent nutritional deficiencies encountered in clinical practice, particularly affecting infants, children, and women of reproductive age. What has changed most significantly in recent years is the recognition that iron deficiency exists along a spectrum and that clinically meaningful symptoms can occur well before anemia develops. 

Patients with iron deficiency may present with fatigue, decreased exercise tolerance, cognitive impairment, and reduced productivity even when hemoglobin levels remain within normal limits. This has led to growing awareness that relying exclusively on hemoglobin as a screening tool may delay diagnosis and treatment. 

One of the most important updates in this area involves the use of ferritin as a primary screening biomarker. Ferritin reflects iron stores and allows for earlier detection of deficiency. In addition, updated guidance suggests that traditional ferritin thresholds were too conservative. Whereas a ferritin level below 15 ng/mL was historically used to define iron deficiency, more recent recommendations support higher thresholds—often below 30 ng/mL or even 45 ng/mL in the presence of anemia—to improve diagnostic sensitivity. 

This shift is particularly relevant in patients with chronic inflammatory conditions, where ferritin may be falsely elevated. In such cases, combining ferritin with transferrin saturation (TSAT) improves diagnostic accuracy and helps distinguish between true iron deficiency and anemia of chronic disease. 

Screening recommendations are also evolving. While universal screening in asymptomatic adults is not yet widely endorsed, there is increasing momentum toward more proactive screening in high-risk populations. These include infants, who are typically screened for anemia around 12 months of age, as well as pregnant individuals, who undergo routine hematologic evaluation during prenatal care. Increasingly, clinicians are also considering ferritin testing early in pregnancy to detect iron deficiency before anemia develops. 

Adolescent females and women of reproductive age represent another key group in whom expanded screening is gaining traction. Menstrual blood loss places these patients at higher risk, and earlier detection of iron deficiency may improve both clinical outcomes and quality of life. In adults more broadly, targeted screening is often appropriate in patients presenting with fatigue, chronic disease, or other nonspecific symptoms.

Anemia: Refining Evaluation and Clinical Approach

Although anemia screening continues to rely on hemoglobin and hematocrit measurements, the approach to evaluation has become more sophisticated. Rather than treating anemia empirically, current best practices emphasize identifying the underlying cause. 

Iron deficiency remains the most common etiology, but clinicians must also consider other contributors such as chronic inflammation, vitamin B12 or folate deficiency, renal disease, and occult blood loss. In particular, iron deficiency anemia in adult men and postmenopausal women warrants careful investigation, as it may be the first sign of gastrointestinal pathology, including malignancy. 

Recent guidance supports a more structured diagnostic approach in these patients, including evaluation for gastrointestinal sources of bleeding, screening for celiac disease, and testing for Helicobacter pylori infection when appropriate. This reflects a growing recognition that anemia is often a symptom of an underlying condition rather than a diagnosis in itself. 

In pediatric populations, anemia screening continues to play a critical role in early development. Iron deficiency anemia in infancy and early childhood has been associated with long-term cognitive and behavioral consequences. As a result, routine screening during the first year of life remains a key preventive measure, with additional risk-based screening throughout childhood. 

A notable trend in both adult and pediatric care is the increasing recognition of non-anemic iron deficiency as a clinically significant condition. This has implications for both screening and management, as earlier intervention may prevent progression to anemia and mitigate associated symptoms.

Lead Screening: Lower Thresholds and Increased Awareness

Perhaps the most significant shift in screening practices relates to lead exposure. Over the past decade, accumulating evidence has reinforced the concept that there is no safe level of lead exposure, particularly in children. Even low blood lead levels have been associated with adverse neurodevelopmental outcomes, including reduced IQ, attention deficits, and behavioral challenges. 

In response to this evidence, public health authorities have lowered the blood lead reference value to 3.5 µg/dL. This change reflects a move toward identifying and addressing exposure at earlier stages, rather than waiting for higher, more overtly toxic levels. 

Screening recommendations vary based on population and geographic risk, but several key principles apply. Children enrolled in Medicaid are required to undergo lead screening at 12 and 24 months of age, while many states recommend universal screening for all children at similar intervals, particularly in high-risk areas. For children who have not been previously screened, catch-up testing is recommended. 

Testing typically begins with a capillary blood sample, which offers convenience and accessibility in pediatric and primary care settings. If the capillary blood sample returns elevated results, the patient should have additional testing via a venous sample to confirm toxicity levels. 

Management of elevated lead levels has also evolved. At lower levels, intervention focuses on education, environmental assessment, and nutritional optimization. As levels increase, more intensive monitoring and intervention are required, with chelation therapy reserved for significantly elevated cases. 

An important and often underrecognized connection exists between lead exposure and iron deficiency. Iron-deficient individuals absorb lead more readily, which can exacerbate toxicity. As a result, screening for iron deficiency is recommended in patients with elevated lead levels, and addressing nutritional deficiencies is an essential component of management.

Integrating Screening into Primary Care Workflows

For primary care physicians, one of the key challenges is integrating these evolving screening recommendations into already busy clinical workflows. Fortunately, many opportunities exist to align screening with routine preventive care visits. 

In pediatric practice, well-child visits provide a natural framework for screening. At approximately 12 months of age, children are typically screened for anemia and undergo initial lead testing. Repeat lead screening is often performed at 24 months, with additional risk-based screening as needed throughout early childhood. 

In adolescent care, particularly for female patients, clinicians may consider incorporating ferritin testing into routine evaluations, especially in those with symptoms suggestive of iron deficiency or with known risk factors such as heavy menstrual bleeding.

In adult primary care, screening is often more individualized. Patients presenting with fatigue, chronic illness, or risk factors for nutritional deficiency may benefit from evaluation that includes a complete blood count and iron studies. Rather than ordering isolated tests, clinicians are increasingly adopting a more comprehensive approach that combines multiple relevant biomarkers to improve diagnostic yield and reduce the need for repeat testing.

What’s Changing—and Why It Matters

Across all three domains—iron deficiency, anemia, and lead exposure—a common theme is emerging: the importance of earlier detection and intervention. Advances in our understanding of disease progression and risk have highlighted the limitations of traditional screening thresholds and approaches. 

In iron deficiency, this has led to a greater emphasis on ferritin testing and the recognition of non-anemic deficiency as clinically meaningful. In anemia, it has prompted more thorough evaluation to identify underlying causes rather than relying on empiric treatment. In lead screening, it has resulted in lower thresholds for concern and a broader focus on environmental and social determinants of health. 

These changes are not merely academic. They have direct implications for patient outcomes, particularly in vulnerable populations such as young children, pregnant individuals, and patients with limited access to care. By identifying disease earlier and addressing contributing factors more comprehensively, primary care physicians have the opportunity to improve both short- and long-term health outcomes.

Future Directions

Looking ahead, several trends are likely to further shape screening practices. Advances in point-of-care testing may soon allow for rapid, in-office assessment of ferritin and other biomarkers, reducing barriers to early detection. At the same time, increasing integration of electronic health record tools may enable more precise risk stratification, helping clinicians identify patients who would benefit most from screening. 

There is also growing interest in developing formal guidelines for the diagnosis and management of iron deficiency without anemia, which could further expand screening recommendations. In the realm of lead exposure, continued collaboration between healthcare providers and public health agencies will be essential for identifying and mitigating environmental risks.

Conclusion

Screening for iron deficiency, anemia, and lead exposure is undergoing a meaningful transformation. The traditional focus on detecting overt disease is being replaced by a more proactive, prevention-oriented approach that emphasizes early identification, improved diagnostic tools, and individualized risk assessment. 

For primary care physicians, this evolution underscores the importance of thinking beyond hemoglobin alone, incorporating updated ferritin thresholds, and recognizing the clinical significance of low-level lead exposure. By integrating these insights into routine practice, clinicians can enhance their ability to detect and address these common but often underrecognized conditions. 

Ultimately, these changes represent an opportunity to deliver more effective, patient-centered care—improving outcomes through earlier intervention and a deeper understanding of the factors that contribute to disease.